GMAB vs IDYA Stock Comparison
GMAB currently leads IDYA in this stock comparison, with AIQ scores of 77 vs 54. The clearest difference is value.
What is the main difference between GMAB and IDYA?
GMAB leads the current stock comparison as Genmab A/S, with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Genmab A/S vs IDEAYA Biosciences, Inc.
GMAB leads
GMAB leads by 23 AIQ points, primarily on Value and Momentum, and the lead has widened from 14 points over 30 sessions. Wall Street currently favors IDYA on target upside.
Competitive: 3 of 6 evidence groups support GMAB, its lead is widening, and its current signal state is conflicted.
Genmab A/S
IDEAYA Biosciences, Inc.
The Algovestiq AIQ Score currently favors GMAB over IDYA, 77 versus 54 as of Nov 15, 2026. GMAB's advantage is driven primarily by stronger value and momentum. GMAB also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors IDYA. 3 of 6 covered evidence groups favor GMAB today, and the comparison is rated Competitive on stability: only 3 of 6 covered evidence groups agree. GMAB lead: Strengthening — the AIQ differential moved from 14 to 23 points over 30 sessions.
Compare Genmab A/S and IDEAYA Biosciences, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare GMAB and IDYA against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value71 vs 39GMAB +32
- Momentum94 vs 63GMAB +31
- Quality72 vs 51GMAB +21
- Risk Resilience58 vs 61Even
3 of 6 evidence groups favor GMAB. GMAB’s edge is concentrated in value and momentum.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
No factor moved materially.
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.57x)
Largest factor move: Value +2, not enough on its own to move the overall score.
New signals
- ADX Trend Strengthening — neutral, trend, medium horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
- OBV Bullish Divergence — bullish, volume, medium horizon (-3.1%)
GMAB's lead narrowed by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — GMAB and IDYA both carry a full feed there.
The central trade-off
GMAB (Genmab A/S): the stronger current systematic profile, led by value and momentum.
IDYA (IDEAYA Biosciences, Inc.): the counter-case, on analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
GMABGMAB on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
EvenGrowth figures are not covered for both names.
Value
GMABGMAB on the peer-relative Value factor, by 32 points.
Momentum
GMABGMAB on the Momentum factor, by 31 points.
Lower downside
IDYAIDYA carries the lower 1-month annualized volatility.
Analyst upside
IDYAIDYA on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors GMAB, analyst targets favor IDYA. That disagreement is the most useful thing on this page.
| Measure | GMAB | IDYA | Note |
|---|---|---|---|
| Implied upside to target | +8% | +53.2% | IDYA has more room |
| Target dispersion | +50.5% | +36.9% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 13 | 16 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor GMAB. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | GMAB | 77 vs 54 |
| Fundamentals | Even | revenue growth 2.8% vs 15.6%; TTM ROE 5.4% vs -11.5%; gross margin 92.6% vs 100%; operating margin 30.5% vs -12.7% |
| Valuation | GMAB | Value 71 vs 39 |
| Technicals | GMAB | Price vs 50-day 24.8% vs -10.3%; vs 200-day 62.9% vs -6% |
| Risk Resilience | Even | Risk Resilience 58 vs 61 |
| Analyst expectations | IDYA | Target upside 8% vs 53.2% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of GMAB and IDYA and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is wide at 23 points. (supports the conclusion holding)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been widening. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on GMAB.
How the comparison changed
120 daily snapshots · May 27 – Nov 13GMAB lead: Strengthening — the AIQ differential moved from 14 to 23 points over 30 sessions.
- Today
- GMAB +23
- 77 vs 54
- 7 sessions ago
- GMAB +25
- 79 vs 54
- 30 sessions ago
- GMAB +14
- 77 vs 63
- 90 sessions ago
- GMAB +3
- 68 vs 65
The lead changed hands 2 times in this window, most recently on Jun 25 when GMAB moved ahead of IDYA.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 3 bearish / 1 neutral, conflicted
Only GMAB
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.57x)
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
- RSI Bearish Divergence — bearish, momentum, medium horizon
- Uptrend Structure Active — bullish, trend, long horizon
4 bullish / 0 bearish / 2 neutral
Only IDYA
- ADX Trend Strengthening — neutral, trend, medium horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
- OBV Bullish Divergence — bullish, volume, medium horizon (-3.1%)
- RSI Bullish Divergence — bullish, momentum, medium horizon
Both carry 2 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode.
GMAB leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved down over the latest session (price -0.72%, AIQ -1 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.08%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1IDYA closes the Value gap — currently 32 points behind, the largest single contributor to GMAB's edge.
- 2IDYA generates a confirmed bullish trend signal it does not currently carry, such as MACD Bullish Crossover or EMA Ribbon Expansion Bullish.
- 3GMAB's conflicting signal state resolves bearish — it currently carries 3 bullish and 3 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
Split| Metric | GMAB | IDYA |
|---|---|---|
| Revenue growth (YoY) | 2.8% | 15.6% |
| EPS growth (YoY) | 14.3% | 0% |
| Gross margin | 92.6% | 100% |
| Operating margin | 30.5% | -12.7% |
| Return on equity (TTM) | 5.4% | -11.5% |
| Debt to equity | 0.82 | 0.03 |
Performance
GMAB leads 5 of 6 windows| Metric | GMAB | IDYA |
|---|---|---|
| 1 week (5 sessions) | -4.2% | 1.9% |
| 1 month (20 sessions) | 38.8% | -3.1% |
| 3 months (63 sessions) | 56.4% | -12.9% |
| 6 months (126 sessions) | 93.6% | 12.8% |
| Year to date | 66.8% | -7.9% |
| 1 year (252 sessions) | 68.6% | -0.4% |
Technicals
GMAB has the stronger structure| Metric | GMAB | IDYA |
|---|---|---|
| RSI (14) | 59.1 | 42.4 |
| ADX (14) | 45.8 | 25.8 |
| Price vs 50-day | 24.8% | -10.3% |
| Price vs 200-day | 62.9% | -6% |
| Volatility (1M, annualized) | 110.9% | 48.2% |
Risk
Split| Metric | GMAB | IDYA |
|---|---|---|
| Beta | 0.93 | 0.94 |
| Sharpe ratio | 1.29 | 0.14 |
| Sortino ratio | 2.53 | 0.2 |
| Max drawdown | -32.5% | -27.8% |
| Current drawdown | -10.3% | -25.1% |
| Annualized volatility | 45.9% | 44.9% |
| Value at risk (95%) | -3.2% | -4.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, GMAB or IDYA?
On the Algovestiq AIQ Score, GMAB is the stronger of the two as of Nov 15, 2026, scoring 77 against IDYA's 54. The edge comes from value and momentum. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is GMAB or IDYA the better buy right now?
GMAB carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 3 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor GMAB over IDYA?
The composite weights Quality, Value, Momentum and Risk Resilience. GMAB leads Value by 32 points; GMAB leads Momentum by 31 points; GMAB leads Quality by 21 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, GMAB or IDYA?
Analyst price targets imply +8% upside for GMAB and +53.2% for IDYA, so the Street currently favors IDYA. That points the opposite way to the AIQ Score, which favors GMAB. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, GMAB or IDYA?
GMAB is the better-valued of the two on the peer-relative Value factor. GMAB on the peer-relative Value factor, by 32 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, GMAB or IDYA?
Growth figures are not covered for both names. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, GMAB or IDYA?
GMAB on the Momentum factor, by 31 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, GMAB or IDYA?
IDYA is the more resilient of the two, so the other name carries the higher downside risk. IDYA carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is GMAB more profitable than IDYA?
The profitability evidence is mixed: gross margin 92.6% vs 100%; operating margin 30.5% vs -12.7%; ttm roe 5.4% vs -11.5%. GMAB leads on two measures and IDYA on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is GMAB's lead over IDYA getting stronger or weaker?
GMAB lead: Strengthening — the AIQ differential moved from 14 to 23 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 2 times in that window, most recently on 2026-06-25, when GMAB moved ahead of IDYA.
What would change the GMAB vs IDYA verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: IDYA closes the Value gap — currently 32 points behind, the largest single contributor to GMAB's edge; IDYA generates a confirmed bullish trend signal it does not currently carry, such as MACD Bullish Crossover or EMA Ribbon Expansion Bullish; GMAB's conflicting signal state resolves bearish — it currently carries 3 bullish and 3 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about GMAB and IDYA?
GMAB: 3 bullish / 3 bearish / 1 neutral, conflicted. IDYA: 4 bullish / 0 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on GMAB is Golden Cross Active (bullish, long horizon). On IDYA it is Golden Cross Active (bullish, long horizon).
Compare GMAB and IDYA with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.